Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE0005664809
Wed, 11.12.2024
Evotec SE
Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing on cardiometabolic diseases
LAB eN² is also expanding, adding Boston Children’s Hospital, Boston University, Johns Hopkins University, Jos [ … ]
Fri, 29.11.2024
Evotec SE
Dr Craig Johnstone steps down as Chief Operating Officer effective 31 December 2024
Distribution of responsibilities internally
Hamburg, Germany, 29 November 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that its Chief Operating Officer, Dr Craig Johnstone, will step down and leave th [ … ]
Wed, 06.11.2024
Evotec SE
Guidance for 2024 confirmed with full-year 2024 revenue and adjusted EBITDA targets on track, despite challenging market conditions
Robust growth of Just - Evotec Biologics driven by roll out of projects together with Sandoz and progress of discovery partnerships
Successful extensions & expansions with BMS and Novo Nordisk; new collaboration [ … ]
Tue, 05.11.2024
Evotec SE
Evotec divests chemical API-focused CDMO operation in Halle/Westphalia (Evotec DS) to Monacum Partners
Transaction aligns with Evotec’s strategic optimization efforts, concentrating resources on key growth drivers
New ownership committed to maintaining and growing the business
Hamburg, 05 November 2024:
Evotec SE (Frankfur [ … ]
Wed, 30.10.2024
Evotec SE
Hamburg, Germany, 30 October 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for the first nine months of 2024 on Wednesday, 06 November 2024.
The Company is going to hold a conference call to discuss 9-months results as well as to provide an overview on the ongoing [ … ]
Wed, 23.10.2024
Evotec SE
Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncology
Evotec receives a US$ 50 m payment from Bristol Myers Squibb; potential programme-based milestone payments contribute to the deal value
Hamburg, Germany, 23 October 2024:
Evotec SE (Frankfurt Stock Exchange: EV [ … ]
Thu, 26.09.2024
Evotec SE
Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies
Hamburg, Germany, 26 September 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that Evotec has entered a techn [ … ]
Fri, 20.09.2024
Evotec SE
J.POD® Toulouse, France (EU) brings disruptive, scalable continuous biologics manufacturing technology to the region
Just – Evotec Biologics’ J.POD® technology offers a paradigm shift in biomanufacturing with cost-effective and flexible clinical and commercial supply solutions
Hamburg, Germany, and Toulouse, France, 20 Septemb [ … ]
Fri, 20.09.2024
Evotec SE
J.POD® Toulouse, France (EU) brings disruptive, scalable continuous biologics manufacturing technology to the region
Just – Evotec Biologics’ J.POD® technology offers a paradigm shift in biomanufacturing with cost-effective and flexible clinical and commercial supply solutions
Hamburg, Germany, and Toulouse, France, 20 Septemb [ … ]
Tue, 03.09.2024
Evotec SE
Dr Matthias Evers steps down as Chief Business Officer effective 01 October 2024
Distribution of responsibilities across other Management Board functions
Hamburg, Germany, 03 September 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that its Chief Business Officer, [ … ]